Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 145,550 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committee. The inducement awards were granted on January 10, 2025. The options have a ten (10) year term and an exercise price of $17.85 per share, the closing price per share of the Company's common stock as reported by Nasdaq on J

Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, January 13, 2025 at 3:00 PM PT. Robert W. Duggan, Chairman and Chief Executive Officer, and Dr. Maky Zanganeh, Chief Executive Officer and President, will present a corporate overview and an update on the progress of our organization, including the development of our innovative investigational bispecific antibody, ivonescimab. The presentation will be available live from our website: www.smmttx.com. An archived version of the presentation will be available on our websi

Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 98,000 shares of common stock. Awards were made to six new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committee. The inducement awards were granted on December 10, 2024. The options have a ten (10) year term and an exercise price of $17.97 per share, the closing price per share of the Company's common stock as reported by Nasdaq on De

Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at the 7th Annual Evercore HealthCONx Conference and Citi's 2024 Global Healthcare Conference, both being held in Miami. Our management team will participate in fireside chats surrounding the development of our innovative investigational bispecific antibody, ivonescimab, at the Evercore HealthCONx Conference on Tuesday December 3, 2024 at 8:45am ET, and the Citi Global Healthcare Conference on Wednesday December 4, 2024 at 8:45am ET. Presentations from both conferences will be available live from our website: www.smmttx.com. An archived version of both presenta

Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 227,600 shares of common stock. Awards were made to 15 new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committee. The inducement awards were granted on November 15, 2024. The options have a ten (10) year term and an exercise price of $18.31 per share, the closing price per share of the Company's common stock as reported by Nasdaq on No

Ivonescimab Monotherapy Became First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab Monotherapy in a Phase III Randomized Clinical Trial in NSCLC, HARMONi-2, Reducing Risk of Disease Progression or Death by 49% in First-Line PD-L1 Positive Advanced NSCLC in China Enrollment Completed in Global Phase III HARMONi Trial in 2L+ EGFRm Advanced NSCLC; Received Fast Track Designation from FDA; Topline Data Expected in Mid-2025 Summit Intends to Expand HARMONi-3 Global Phase III Trial in 1L Metastatic NSCLC to Include Patients with Tumors of Non-Squamous Histology in Addition to Currently Enrolling Squamous Patients Summit to Initiate Global Phase III HARMONi-7 Trial in 1L PD-L

Nuvectis Pharma (NASDAQ:NVCT) continues to make strides in precision oncology, gaining momentum following presentations last week at the AACR-NCI-EORTC Symposium where its drug candidate NXP900 demonstrated strong synergy with ALK inhibitors in non-small cell lung cancer (NSCLC) cells that despite being driven by ALK fusions, are resistant to treatment with the market leading ALK Inhibitors, alectinib and lorlatinib, showcasing NXP900's potential to address resistance mechanisms in NSCLC. Also, with the growing anticipation of the data update from NXP800 expected soon from the Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, Nuvectis is positioning itself at the forefron

Conference Call to be Held at 9:00am ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its third quarter 2024 financial results and provide an operational update for the Company on Wednesday, October 30, 2024, before the market opens. Summit will host a live webcast of the earnings conference call at 9:00am ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our website. About Ivonescimab Ivonescimab, known as SMT112 in Summit's license territories, the United States, Canada, Europe, Japan, Latin America, including Mexico and all countries in Central Am

Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 249,550 shares of common stock. Awards were made to ten new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committee. The inducement awards were granted on October 1, 2024. The options have a ten (10) year term and an exercise price of $20.10 per share, the closing price per share of the Company's common stock as reported by Nasdaq on Oct

FDA Grants Fast Track Designation for Ivonescimab in 2L+ EGFRm NSCLC HARMONi Completed Enrollment for Summit's First Sponsored Study Evaluating Ivonescimab Topline data from the HARMONi Trial Is Expected in Mid-2025 Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that we have completed enrollment in our HARMONi clinical trial, a multi-regional Phase III study sponsored by Summit evaluating ivonescimab plus platinum-doublet chemotherapy vs. placebo plus platinum-doublet chemotherapy with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatmen

Truist initiated coverage of Summit Therapeutics with a rating of Buy and set a new price target of $35.00

Wells Fargo initiated coverage of Summit Therapeutics with a rating of Overweight and set a new price target of $30.00

Jefferies initiated coverage of Summit Therapeutics with a rating of Buy and set a new price target of $31.00

JMP Securities initiated coverage of Summit Therapeutics with a rating of Mkt Outperform and set a new price target of $32.00

Citigroup downgraded Summit Therapeutics from Buy to Neutral and set a new price target of $23.00 from $19.00 previously

H.C. Wainwright initiated coverage of Summit Therapeutics with a rating of Buy and set a new price target of $16.00

Citigroup initiated coverage of Summit Therapeutics with a rating of Buy and set a new price target of $7.00

Stifel initiated coverage of Summit Therapeutics with a rating of Buy and set a new price target of $8.00

Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. "It is an honor to add Jeff Huber to our excellent, diverse group of board members," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Jeff's executive leadership experience in healthcare and technology and his countless accomplishments evidence his ability to translate what's possible into transformational success. As we seek to change the standard of care for solid tumors based on the potential of ivonescimab, we are thrilled to supplement our outstanding leadership team with a board member

Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. "We are excited to add Dr. Ronaghi to complement our excellent group of current board members," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Mostafa has valuable experience in translating innovative concepts in genomics and sequencing that ultimately lead to advancements in patient care through his work at Illumina, Grail, and his continuing ventures. As we intend to maximize the potential of ivonescimab, we are excited to add the acumen and expertise that Mostafa can bring to

Joydeep Goswami to serve as advisor through June 30 Illumina reaffirms Q1 2024 and full-year 2024 financial guidance SAN DIEGO, April 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided to leave Illumina. He will stay on in an advisory role through June 30 to support two new executive management team appointments. Ankur Dhingra is joining Illumina as Chief Financial Officer (CFO), leading Illumina's financial planning and analysis, accounting, investor relations,

Mr. Soni Invests $5 Million in Summit while Joining Executive Team In Corresponding Appointments, Dave Gancarz, Urte Gayko, PhD, Fong Clow, DSc, & Allen S. Yang, MD, PhD, Elevated to Newly Established Leadership Roles Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Manmeet S. Soni has been appointed as the Company's Chief Operating Officer, effective immediately. Mr. Soni will remain a member of the Company's Board of Directors. "Manmeet Soni has few peers in this industry, and his track record speaks for itself," stated Dr. Maky Zanganeh, Chief Executive Officer and President of Summit. "With our focus on bringing to life our mission to

Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Dr. Alessandra Cesano, MD, PhD, has been appointed to its Board of Directors, effective immediately. "Dr. Cesano compliments our Board of Directors with her decades of extensive experience in the global clinical development of oncology drugs," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "As we intend to expand our pipeline product portfolio into oncology, we are excited to add the wisdom and expertise that Alessandra can bring to our impressive leadership team. Her experience in developing both large and

Menlo Park, California, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Dr. Robert Booth, PhD, has been appointed to its Board of Directors, effective immediately. Dr. Booth initiated the BTK inhibitor program at Celera Genomics, Inc. that ultimately became Pharmacyclics, Inc.'s IMBRUVICA® (ibrutinib), the blockbuster drug that changed the paradigm of treatment for many hematological cancers. "Our world class executives and leaders at Team Summit continue to demonstrate our convening power in our ability to attract such a stellar talent as Dr. Booth," said Robert W. Duggan, Chairman and Chief Executive O

Menlo Park, California, July 26, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ:SMMT) announces that Dr. Maky Zanganeh, DDS, MBA, has been appointed as Co-Chief Executive Officer & President, effective immediately.  Dr. Zanganeh was formerly the Company's Chief Operating Officer, having served in that capacity since she joined the Company as an employee in November 2020, and remains a member of the Company's Board of Directors.  "Maky defines what it means to be a great leader," said Robert W. Duggan, Executive Chairman and Chief Executive Officer of Summit. "We have assembled a world-class leadership team here at Summit and have guided a group of accomplished executives

Cambridge, MA, June 01, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ:SMMT) today announced that Ankur Dhingra has been appointed as Chief Financial Officer, effective immediately. "We are in a pivotal time for Team Summit as we seek to expand our portfolio of pipeline assets through potential collaborations and possible acquisitions," said Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Ankur's leadership and experience will be critical in ensuring the financial viability and excellence of our organization. Ankur's wealth of knowledge across all aspects of finance will add substantial value to our organization as we take the next step in seeking to make

Cambridge, MA, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ:SMMT) today announced that Kenneth A. Clark, JD, has been appointed to our Board of Directors, effective immediately. Mr. Clark is currently a partner at Wilson Sonsini Goodrich & Rosati (WSGR) based out of the firm's Palo Alto, CA, office. At WSGR, Ken advises biotech companies in strategic partnerships, mergers and acquisitions, and financing transactions, in addition to a range of other matters. He has previously served as a member of the boards of directors for multiple publicly traded companies, including Pulse BioSciences, Inc. and Pharmacyclics, Inc., in addition to serving two terms on WSGR's Bo

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

4 - Summit Therapeutics Inc. (0001599298) (Issuer)